Add BrightSurf on Google Email

Researchers uncover evolutionary forces at play in the aging of the blood system and identify people at increased risk of blood cancer

A recent study has uncovered the evolutionary forces at play in the aging of the blood system and identified individuals at increased risk of blood cancer. The research provides a robust indicator for classifying patients with ARCH mutations, allowing for more frequent screening and early treatment.

SourceOntario Institute for Cancer Research·JournalNature Communications·DateAug 17, 2021

Fels and Fox Chase researchers highlight roles of TET2 and DNMT3A mutations in personalized medicine-guided synthetic lethality against leukemia

Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.

SourceTemple University Health System·JournalCancer Research·DateAug 13, 2021

Less stress for women who know their genetic risk for breast cancer

A recent UNSW study found that women who received their polygenic risk score (PRS) for breast cancer experienced minimal regret and reduced distress compared to those who declined. The researchers also discovered that more women reported regret about not knowing their PRS score, highlighting the importance of providing clear informatio...

SourceUniversity of New South Wales·JournalGenetics in Medicine·TypeSurvey·DateAug 9, 2021

Geneticists outline plan to boost diversity, inclusion in their field

A group of geneticists have outlined a plan to increase diversity and inclusion in their community, including boosting representation at academic conferences and addressing obstacles for underrepresented groups in research labs. The action plan aims to improve equity and fairness in the field of genetics and beyond.

SourcePLOS·JournalPLOS Genetics·DateJul 15, 2021

Genetic study of liver cancer reveals new drug target

A recent genetic study published in PLOS Genetics has identified MAGEA3, a gene associated with poor prognosis in liver cancer, as a potential target for new treatments. The study found that blocking the expression of MAGEA3 in liver cancer cells can prevent their growth and death, offering hope for developing new therapies.

SourcePLOS·JournalPLOS Genetics·DateJun 24, 2021

Cancer immunotherapy approach targets common genetic alteration

Researchers developed a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers. The approach stimulates an immune response against cells with the loss of one gene copy, called loss of heterozygosity (LOH), and has shown promising results in laboratory studies and mouse models.

SourceJohns Hopkins Medicine·JournalProceedings of the National Academy of Sciences·DateMar 15, 2021

New findings speed progress towards affordable gene therapy

Researchers have developed a new method for deploying CRISPR/Cas9 directly into target cells using metal-organic frameworks (MOFs) coated with green tea phytochemicals. This approach has the potential to reduce costs and increase safety compared to existing viral methods, which are currently the only approved methods in trial globally.

SourceRMIT University·JournalChemical Communications·DateNov 20, 2020